Cyberounds Logo
September 28, 2020 | LOGIN | REGISTER | HELP | 
email a friend print Bookmark and Share
Managing Proteinuria in Progressive Diabetic Nephropathy
CME credit is no longer available for this conference.
Eli A. Friedman, M.D.

Within the past three years, Dr. Friedman has received grant/research support from Alteon.


Release Date: 06/03/2002
Termination Date: 06/03/2002

Estimated time to complete: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
 
Learning Objectives
Upon completion of this Cyberounds®, you should be able to:
  • Classify and chart the course of proteinuria in the nephropathy complicating type 1 and type 2 diabetes
  • Discuss the timing and value of interventions that retard the progression of diabetic nephropathy, highlighting the value of drugs that impede the rennin-angiotensin system
  • Stage the course of diabetic nephropathy planning timing of therapy for chronic renal failure.

 
This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
 
Please click below to accept the terms of this CME activity